임상시험 트래커
추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov
기업
37건 표시
- 3상모집 예정· HIV InfectionDuo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated Strategy
협력: 길리어드
- 3상모집 예정· TalaromycosisLiposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)
협력: 길리어드
- 3상모집 중· Relapsed or Refractory Large B-cell LymphomaStudy Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy
협력: 길리어드
- 3상모집 중단 (진행 중)· HIV Pre-exposure ProphylaxisStudy of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)
리드: 길리어드
- 3상모집 중· Extensive Stage Small Cell Lung Cancer (ES-SCLC)Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
리드: 길리어드
- 3상모집 중· Disseminated Histoplasma Capsulatum InfectionEfficacy and Safety of High-dose Liposomal Amphotericin B for Disseminated Histoplasmosis in AIDS
협력: 길리어드
- 3상모집 중· Triple Negative Breast CancerNeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
협력: 길리어드, 머크(MSD)
- 3상모집 중단 (진행 중)· HIV-1-infectionStudy to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1
리드: 길리어드 · 협력: 머크(MSD)
- 3상모집 중단 (진행 중)· HIV-1-InfectionStudy to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1
리드: 길리어드 · 협력: 머크(MSD)
- 3상모집 중단 (진행 중)· Multiple MyelomaA Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
협력: 길리어드
- 3상모집 중단 (진행 중)· HIV-1-infectionStudy to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy
리드: 길리어드
- 3상모집 중· Triple Negative Breast CancerSafety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer
협력: 길리어드
- 3상모집 중· Primary Biliary CholangitisSeladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
리드: 길리어드
- 3상모집 중단 (진행 중)· Locally Advanced or Unresectable Metastatic Breast CancerStudy of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
리드: 길리어드
- 3상모집 중단 (진행 중)· High-risk Large B-cell Lymphoma (LBCL)Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
협력: 길리어드
- 3상모집 중단 (진행 중)· Carcinoma, Non-Small-Cell LungStudy of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
리드: 머크(MSD) · 협력: 길리어드
- 3상모집 중· Triple Negative Breast CancerStudy of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
리드: 길리어드
- 3상모집 중단 (진행 중)· Advanced Upper Gastrointestinal Tract AdenocarcinomaA Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
협력: 길리어드
- 3상모집 중단 (진행 중)· Non-small Cell Lung CancerZimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
리드: 길리어드
- 3상모집 중단 (진행 중)· Relapsed/Refractory Follicular LymphomaStudy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
협력: 길리어드
- 3상모집 중단 (진행 중)· Triple Negative Breast CancerStudy of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
리드: 길리어드 · 협력: 머크(MSD)
- 3상모집 중단 (진행 중)· Triple Negative Breast CancerStudy of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
리드: 길리어드
- 3상모집 중단 (진행 중)· Non-Small Cell Lung CancerStudy of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
리드: 길리어드
- 3상모집 중단 (진행 중)· Pre-Exposure Prophylaxis of HIV InfectionPre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection
리드: 길리어드
- 3상모집 중단 (진행 중)· Pre-Exposure Prophylaxis of HIV InfectionStudy of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection
리드: 길리어드
- 3상모집 중단 (진행 중)· Metastatic Breast CancerAsian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)
리드: 길리어드
- 3상모집 중단 (진행 중)· HER2-negative Breast CancerSacituzumab Govitecan in Primary HER2-negative Breast Cancer
협력: 길리어드
- 3상모집 중단 (진행 중)· Primary Biliary CirrhosisStudy of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)
리드: 길리어드
- 3상모집 중단 (진행 중)· Ulcerative ColitisFilgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis
협력: 길리어드
- 3상모집 중단 (진행 중)· Pre-Exposure Prophylaxis of HIV-1 InfectionStudy to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection
리드: 길리어드
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.